

Corporate Medical Policy

Esophageal Pathology Testing AHS – M2171

File Name: esophageal_pathology_testing
Origination: 04/2020
Last CAP Review: 11/2021
Next CAP Review: 11/2022
Last Review: 11/2021

Description of Procedure or Service

Description

The esophagus is a long tube that serves to connect the mouth to the stomach. Although the esophagus is primarily a connecting organ, it experiences significant chemical and mechanical trauma. The esophagus has mechanisms and structures to withstand this damage, but molecular injury is common (Zhang et al., 2018). Both serological and genetic markers have been suggested to identify, diagnose, or assess risk in the esophagus.

Eosinophilic esophagitis (EoE) is one such condition, as its nonspecific symptoms (pain, issues swallowing, vomiting, and so on) may be accompanied by inflammatory markers in the esophagus (Bonis & Gupta, 2020). Similarly, esophageal cancer is characterized by several nonspecific symptoms, while a predecessor condition, Barrett esophagus (BE), may have no clinical symptoms at all (Saltzman & Gibson, 2018; Spechler, 2020).

Related Policies

Molecular Panel Testing of Cancers for Diagnosis, Prognosis, and Identification of Targeted Therapy AHS – M2109

*****Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.**

Policy

BCBSNC will provide coverage for esophageal pathology testing when it is determined to be medically necessary because the medical criteria and guidelines shown below are met.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Esophageal Pathology Testing is covered

1. Reimbursement is allowed for analysis of PD-L1 expression by immunohistochemistry in esophageal, gastric, or esophagogastric junction cancer tumors before first-line therapy PD-1 inhibitors, such as pembrolizumab, in patients with locally advanced, recurrent, or metastatic disease (See Notes 1 & 2).

Esophageal Pathology Testing AHS – M2171

2. Microsatellite instability analysis or MMR analysis is considered medically necessary for individuals with locally advanced, recurrent, or metastatic esophageal, gastric, or esophagogastric junction cancer for whom PD-1 inhibitors, such as pembrolizumab, are being considered for therapy (See Notes 1 & 2).
3. Genetic testing of *HER2* is considered medically necessary for individuals with esophageal, gastric, or esophagogastric junction cancer for whom trastuzumab is being considered for therapy (See Notes 1 & 2).
4. Testing for *NTRK* gene fusion is considered medically necessary for individuals with esophageal, gastric, or esophagogastric junction cancer before first-line or subsequent therapy with larotrectinib or entrectinib (See Notes 1 & 2).

When Esophageal Pathology Testing is not covered

1. The use of genetic testing, including the use of molecular panel tests and gene expression profiling, to assess the risk of eosinophilic esophagitis (EoE) is considered not medically necessary.
2. The use of genetic testing, including the use of molecular panel tests and gene expression profiling, to diagnose or monitor eosinophilic esophagitis (EoE) is considered not medically necessary.
3. Testing for risk of Barrett's esophagus and/or esophageal, including esophagogastric junction, cancer using a molecular classifier, such as the BarreGEN test, is considered not medically necessary.
4. Reimbursement is not allowed for epigenetic analysis, including but not limited to methylation analysis, of the likelihood for Barrett's esophagus (such as EsoGuard), esophageal, or esophagogastric junction cancer.
5. Reimbursement is not allowed for wide-area transepithelial sampling (WATS-3D) for the determination of risk, the detection, or the prognosis of Barrett's esophagus, esophageal cancers, and/or esophagogastric junction cancers.
6. The use of the Esophageal String Test (EST) to diagnose, assess, or monitor eosinophilic esophagitis (EoE) is considered investigational.
7. Liquid biopsy—the use of a non-invasive blood, saliva, or other body fluid to test for circulating tumor cells (CTCs), cell-free tumor DNA (cfDNA) fragments, and/or ribonucleoprotein complexes—for genomic profiling of esophageal and esophagogastric junction cancers is considered not medically necessary.

Note 1: For guidance on molecular panel testing of cancers, including esophageal and esophagogastric junction cancers, **for targeted therapy**, please see AHS-M2109 Molecular Panel Testing of Cancers for Diagnosis, Prognosis, and Identification of Targeted Therapy.

Note 2: For 5 or more gene tests being run on a tumor specimen (i.e. non-liquid biopsy) on the same platform, such as multi-gene panel next generation sequencing, please refer to AHS-R2162 Reimbursement Policy.

Policy Guidelines

Esophageal Pathology Testing AHS – M2171

Background

The esophagus is a long tube that connects the mouth to the stomach. Its primary function is to transport food from the mouth to the stomach. However, this organ is often exposed to difficult conditions, from abrasive food to the acidic conditions of the stomach. Although mechanisms are in place to protect against injury (namely the tough squamous cells), it is common to see injury or disease in the esophagus (Zhang et al., 2018).

Many serological and genetic markers have been proposed as tools to assist in evaluation of esophageal pathology. Eosinophilic esophagitis (EoE), Barrett's esophagus (BE), and esophageal cancer are typically diagnosed with histological analysis from endoscopic biopsy (Bonis & Gupta, 2020; Saltzman & Gibson, 2018, 2020; Spechler, 2020), but biopsies frequently require careful consideration and resources to perform properly (NCCN, 2019, 2020b). For these reasons, serum and genetic markers have been suggested as noninvasive markers for esophageal pathologies.

Eosinophilic Esophagitis (EoE)

Eosinophilic esophagitis (EoE) marked by the presence of eosinophils in the esophagus. Eosinophils are typically associated with mitigating inflammation but are not normally found in the esophagus. EoE is represented by a broad set of clinical symptoms, such as difficulty swallowing, chest or abdominal pain, and feeding dysfunction. Diagnosis is established through endoscopy with biopsies to confirm eosinophilia. The current diagnostic criteria sets the cutoff for eosinophilia at ≥ 15 eosinophils per high power field, (60 eosinophils per mm^2) although this figure has been heavily discussed (Bonis & Gupta, 2020; Dellon et al., 2018).

Laboratory tests have been suggested as a noninvasive adjunct for EoE. Serum IgE will be elevated in up to 60% of EoE patients, as allergy has a strong association with EoE. Many other markers, such as eotaxin-3, major basic protein-1, tryptase, chemokines, and serum eosinophil count, have all been suggested to assist in evaluation of EoE (Bonis & Gupta, 2020; Dellon et al., 2018). Immune system factors may also contribute to pathology. Since eosinophils are not normally found in the esophagus, their presence in the esophagus may suggest an underlying issue with the immune system. Various interleukins, mast cells, and T cells have all been proposed as contributing to pathogenesis, but the exact pathway and mechanisms are not completely understood (Rothenberg, 2020). Genetic features have also been used for EoE evaluation. Twin studies and family histories have indicated a role for genetics in EoE. Several genes have also been identified as potential risk factors, such as *CAPN14* (an interleukin-13 regulator), *TSLP* (a basophil regulator), and *CCL26* (promotes eosinophil movement into esophagus) (Sherrill & Rothenberg, 2014).

Wen et al. (2013) developed a diagnostic gene expression panel ("EDP") for EoE. The authors identified candidate genes using two cohorts of EoE and control patients, then validated these genes with a separate cohort of 194 patients (91 active EoE, 57 control, 34 ambiguous, 12 reflux). The panel was found to identify EoE patients at 96% sensitivity and 98% specificity. The authors also noted that the panel could separate patients in remission from unaffected patients (Wen et al., 2013).

Shoda et al. (2018) used an "EoE Diagnostic Panel" (EDP) to further classify EoE cases by histologic, endoscopic, and molecular features. The EDP consisted of 95 esophageal transcripts purported to identify EoE among both unaffected patients and patients with other conditions. 185 biopsies were studied. The authors identified three clear subtypes of EoE; subtype 1 with a normal-appearing esophagus and mild molecular changes, subtype 2 with an inflammatory and steroid-responsive phenotype, and subtype 3 with a "narrow-caliber" esophagus and severe molecular alterations. These findings were replicated in a 100-biopsy sample (Shoda et al., 2018).

Esophageal Pathology Testing AHS – M2171

Tests are commercially available for EoE. Noninvasive tests (as an alternative to endoscopy) have been recently popular. The Esophageal String Test (EST) is one such alternative. The patient swallows a gelatin-coated capsule with a string wrapped inside. Once the capsule is in the patient's stomach, the gelatin dissolves, allowing the capsule to pass through. The string itself is used to collect samples from the patient's esophagus and is easily removed from the patient. From there, the sample is analyzed for several biomarkers (major basic protein-1, eotaxins 2 and 3, and so on) to provide a probability% (a trademarked "EoEscore") of esophageal inflammation (Ackerman et al., 2019; EnteroTrack, 2019).

Barrett's Esophagus (BE)

Barrett's esophagus (BE) is a condition in which the normal squamous tissue lining the esophagus is replaced by metaplastic columnar epithelium. This new epithelium contains gastric features and is typically caused by chronic gastroesophageal reflux disease (GERD). This condition predisposes to esophageal cancer. When noxious substances (gastric acid, bile, et al) are exposed to the squamous esophageal tissue, the damage is usually repaired through regeneration of these squamous cells. In BE cases, this damage is repaired not through creation of new squamous cells, but through metaplastic columnar cells. The exact reason for this is unknown. Although these metaplastic cells are more resistant to reflux-based damage than the normal squamous cells, these cells frequently show the oxidative DNA damage that is typical of cancer. Mutations in the p53 tumor suppressor gene appear to be the catalyst for cancers, as acquisition of this mutation in conjunction with the replication of the genome is conducive to carcinogenesis (Spechler, 2020).

Vollmer (2019) performed a review assessing incidence of adenocarcinoma detected during surveillance of BE. The author identified 55 studies encompassing 61371 total patients. Of the 61371 total patients, 1106 developed adenocarcinoma. Overall, the author found that the model created from the studies "predicted the per-person probability of developing cancer in 5 years of complete follow-up is approximately 0.0012". Variables affecting this probability included mean time of follow-up, definition of Barrett metaplasia, and fraction of patients followed up for at least 5 years (Vollmer, 2019).

Proprietary tests are commercially available for assessment of BE, usually to evaluate risk (BE progression to cancer, risk of BE itself, and such). For example, BarreGen, offered by Interpace Diagnostics, uses tumor mutational load (a measure intended to capture total genomic instability of a sample) to calculate risk of progression. Although many ways can estimate mutational load, BarreGen tests 10 key genomic loci which are as follows: "1p (*CMM1*, L-myc), 3p (*VHL*, *HoGG1*), 5q (*MCC*, *APC*), 9p (*CDKN2A*), 10q (*PTEN*, *MXII*), 17p (*TP53*), 17q (*RNF43*, *NME1*), 18q (*SMAD4*, *DCC*), 21q (*TFF1*, *PSEN2*) and 22q (*NF2*)". These loci encompass integral tumor suppressors and are proposed to provide an accurate picture of genomic instability (Interpace, 2019; Trindade et al., 2019). Another test, TissueCypher, also proposes to predict likelihood of progression from BE to esophageal cancer. The test measures 9 protein biomarkers that represent morphological and cellular changes (p53, p16, AMACR, CD68, COX2, HER2, K20, HIF1-alpha, CD45RO). These biomarkers are quantified and converted to a risk score (1-10) and probability of progression (Cernostics, 2021). Finally, a proprietary imaging system, WATS3D, is commercially available. This imaging system samples from a wider area, as opposed to only taking focal samples in a traditional biopsy. This technology also provides a 3-dimensional image of the sampled area. This technology purports to provide more precise sampling than the traditional 4-quadrant biopsies, claiming an increased detection rate of BE and other dysplasias (Diagnostics, 2021).

Esophageal Cancer

Esophageal cancers are largely divided into two groups: squamous cell carcinomas (SCCs) and adenocarcinomas (EAC). SCCs usually begin in the middle of the esophagus, whereas EACs

Esophageal Pathology Testing AHS – M2171

often originate near the gastroesophageal junction. Both share several risk factors, such as smoking. Due to the numerous environmental risk factors for both types of cancer, it is difficult to ascertain the true impact of genetic factors (Gibson, 2020). These cancers are primarily diagnosed through histologic examination, usually obtained through endoscopy (Saltzman & Gibson, 2018, 2020).

Advancements have been in the molecular characterization of both types of cancer. *TP53* mutations are the most common mutation seen in both types of cancer. Other frequently mutated genes in adenocarcinoma include *ELMO1* and *DOCK2* (enhance cell motility), *ARID1A*, *SMARCA4* and *ARID2* (chromatin remodelers), and *SPG20* (traffics growth factor receptors). BE, as the precursor to adenocarcinomas, includes certain similarities in genetic mutations but at a less severe rate. Further, the rate of overlap tended to increase with higher degree of dysplasia (Testa, Castelli, & Pelosi, 2017).

SCC mutations tend to be in genes associated with specific cellular pathways. Genes in ubiquitous pathways, such as *EGFR*, *NOTCH3*, and *RB*, are frequently mutated in SCC. The molecular profile of esophageal SCC tends to align more with other squamous cell cancers (such as head and neck cancers) rather than EAC (Testa et al., 2017). Numerous gene expression studies have been performed to further classify molecular subtypes of esophageal cancer (Gonzaga et al., 2017; McLaren et al., 2017; Visser, Franken, Brosens, Ruurda, & van Hillegersberg, 2017). Gene expression profiles may have utility in assessing response to treatment, prognosis, or risk assessment.

Li, Qi, Hu, and Wang (2019) investigated potential biomarkers for lymph node metastasis for esophageal squamous cell carcinoma. 6 studies encompassing 70 patients were included. The authors identified 9 biomarkers and 4 cellular mechanisms that influence lymph node metastasis. From there, they identified three biomarkers with broader influence on prognosis of disease, *PTEN*, *STMN1*, and *TNFAIP8*. The authors suggested that those three biomarkers should be researched further (Li et al., 2019).

Plum et al. (2019) evaluated *HER2* overexpression's impact on prognosis of esophageal adenocarcinoma (EAC). 428 EAC patients that underwent a "trans thoracic thoraco-abdominal esophagectomy" were included. The authors identified 44 patients with *HER2* positivity (IHC score 3+ or 2+ with gene amplification). This cohort was found to have a better overall survival (OS, 70.1 months vs 24.6 months), along with better histology, absence of lymphatic metastases, and lower tumor stages. The authors also noted a similarity in results to a large 2012 study (Plum et al., 2019).

Frankell et al. (2019) examined the molecular landscape of esophageal adenocarcinoma (EAC). The authors assessed 551 genomically characterized EACs. A total of 77 driver genes and "21 non-coding driver elements" were identified. The authors also found an average of 4.4 driver events per tumor. A three-way association was found, between hyper-mutation, *Wnt* signaling, and loss of immune signaling genes. Finally, the authors also identified "sensitizing events" (events causing a tumor to be more susceptible to a therapy) to CD4/6 inhibitors in over half of the EAC cases studied (Frankell et al., 2019).

Clinical Validity and Utility

Ackerman et al. (2019) evaluated the ability of the 1-hour Esophageal String Test (EST) to distinguish between active eosinophilic esophagitis (EoE), inactive eosinophilic esophagitis, and normal esophagi. 134 patients (62 active EoE, 37 inactive EoE, 35 normal) were included. The authors found that eotaxin 3 measured from both EST samples and the control biopsy extracts to be the best marker for distinguishing active EoE from inactive EoE (by both sensitivity and specificity). Addition of major basic protein 1 (MBP-1) improved sensitivity by 0.039 (0.652 to 0.693) and specificity by 0.014 (0.261 to 0.275) across all patients (Ackerman et al., 2019).

Esophageal Pathology Testing AHS – M2171

Hao, Critchley-Thorne, Diehl, and Snyder (2019) performed a cost-effectiveness analysis of an “adenocarcinoma risk prediction multi-biomarker assay” (TissueCypher’s Barrett’s Esophagus Assay). A hypothetical cohort of 10000 patients with BE diagnoses (including non-dysplastic intestinal metaplasia [NBDE], indefinite for dysplasia [IND], and low-grade dysplasia [LGD]) was created. A Markov decision model was used to compare BE management costs between assay use and the standard of care (SOC). A surveillance interval of 5 years was used. Low-risk patients were found to have a 16.6% reduction in endoscopies. High-risk patients were found to have a 58.4% increase in endoscopic treatments (compared to the SOC arm), leading to a death total of 111 for the assay arm compared to 204 in the SOC arm (a 45.6% reduction). Overall, the authors calculated the incremental cost-effectiveness ratio (ICER) to be \$52,483/quality-adjusted life-year (QALY), and they found that “the probability of the Assay being cost-effective compared to the SOC was 57.3% at the \$100,000/QALY acceptability threshold” (Hao et al., 2019).

Eluri et al. (2018) aimed to validate a genomic panel intended to represent tumor mutational load (TML). Previously, the authors evaluated a panel of 10 genomic loci from which a TML score was calculated. This mean TML was found to be significantly higher in 23 BE patients that had progressed to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) as compared to 46 that had not progressed. The area under the curve in this prior study was found to be 0.95 at a mutational load (ML) cutoff of 1 (on a scale of 1-10). In the present study, 159 subjects were included. Cases had “baseline nondysplastic BE (NDBE) and developed HGD/EAC ≥ 2 years later.” 58 subjects were progressors and 101 were nonprogressors. The authors identified no difference in mean ML in pre-progression tissue in both cohorts (“ML = 0.73 ± 0.69 vs. ML = 0.74 ± 0.61 ”). The area under the curve at the cutoff of ML 1 was only 0.50, and the authors concluded that the “utility of the ML to stratify BE patients for risk of progression was not confirmed in this study” (Eluri et al., 2018).

Trindade et al. (2019) evaluated tumor mutational load’s (ML) ability to “risk-stratify those that may progress from non-dysplastic BE to dysplastic disease”. 28 patients were included, and ML levels were compared between those that progressed to dysplasia and those who had not. 8 total patients progressed to dysplasia (6 low-grade, 2 high-grade), and 7 of these patients had “some level” of genomic stability detected (ML ≥ 5 on a scale of 1 to 10). 10 of the 20 patients that did not progress to dysplasia had “no” ML level. The authors also noted that at an ML of ≥ 1.5 , the risk of progression to high-grade dysplasia was 33%, with a sensitivity of 100% and specificity of 85%. The authors concluded “that ML may be able to risk-stratify progression to high-grade dysplasia in BE-IND. Larger studies are needed to confirm these findings” (Trindade et al., 2019).

Moinova et al. (2018) evaluated the ability of two DNA methylation signatures to detect BE. Methylation signatures of the *VIM* and *CCNA1* loci were evaluated in 173 patients with or without BE. *CCNA1* methylation was found to have an area under the curve of 0.95 for distinguishing BE-related dysplasia compared to normal esophagi. When the data for *VIM* methylation was added, the resulting sensitivity was 95%, and the resulting specificity was 91%. These findings were replicated in a validation cohort of 86 patients, with the combination of methylation markers detecting BE metaplasia at 90.3% sensitivity and 91.7% specificity (Moinova et al., 2018).

Critchley-Thorne et al. (2016) validated a pathology panel to predict progression of BE to esophageal cancer. The authors identified 15 potential biomarkers, which were evaluated in both training and validation sets. This “classifier” separated patients into three different risk classes: low, intermediate, and high in the training set of 183. The authors calculated the hazard ratio of intermediate to low risk at 4.19 and high to low at 14.73. In the validation set (n = 183), the concordance index (an estimation of area under the curve) of the 15-factor classifier was 0.772, the best of the amounts tested (3, 6, 9, 12, 15, 17). The authors also noted that this classifier provided independent prognostic information that were outperformed predictions based on other

Esophageal Pathology Testing AHS – M2171

clinicopathological factors, such as segment length, age, and p53 overexpression (Critchley-Thorne et al., 2016).

Another multicenter study investigated the use of WATS^{3D} with either random or targeted FB in the detection of esophageal dysplasia (ED). 12,899 patients were enrolled in the study, and WATS^{3D} detected an additional 213 cases of ED beyond the initial 88 cases identified by FB, representing an increase of 242%. Regarding screening for BE, WATS increased the overall detection by 153% (from 13.1% to 33% of the individuals enrolled). The authors noted that the order of testing (e.g. FB or WATS) did not impact the results. The authors conclude, “In this study, comprised of the largest series of patients evaluated with WATS, adjunctive use of the technique with targeted and random FB markedly improved the detection of both ED and BE. These results underscore the shortcomings of FB in detecting BE-associated neoplasia, which can potentially impact the management and clinical outcomes of these patients (Smith et al., 2019).”

A study into the cost-effectiveness of WATS^{3D} testing as an adjunct to the standard-of-care forceps biopsy (FB) used a reference case of a 60-year-old white male with gastroesophageal reflux disease (GERD) to see the number of screens needed to avert one cancer and one cancer-related death as well as to calculate the quality-adjusted life years (QALYs) as measured in 2019 U.S. dollars. With this as a reference case, 320 – 337 individuals would need to be screened using WATS^{3D} to avert one cancer, and 328 – 367 individuals would be required to avert one death. The additional cost associated with WATS^{3D} was \$1219, but an additional 0.017 QALYs were produced, resulting in an ICER of \$71395/QALY. The authors conclude, “Screening for BE in 60-year-old white male GERD patients is more cost-effective when WATS^{3D} is used adjunctively to the Seattle protocol than with the Seattle protocol alone (Singer & Smith, 2020).”

One study compared the use of the WATS^{3D} technology to standard forceps biopsy. 117 individuals with a history of Barrett’s esophagus with dysplasia had both techniques performed. For the biopsy, a four-quadrant biopsy quadrant protocol was performed every 1 – 2 cm. Evaluation of the biopsy and the WATS^{3D} technique was performed by separate pathologists, blinded to each other’s results. “Brush biopsy [WATS^{3D}] added an additional 16 position cases increasing the yield of dysplasia detection by 42% (95% CI: 20.7 – 72.7). The number needed to test (NNT) to detect one additional case of dysplasia was 9.4 (95% CI: 6.4 – 17.7).” The authors of the study noted that no statistical difference was evident between medical centers, the type of forceps used, or between sampling every 1 cm versus every 2 cm. They conclude, “These data suggest that computer-assisted brush biopsy is a useful adjunct to standard endoscopic surveillance regimens for the identification of dysplasia in Barrett’s esophagus (Anandasabapathy et al., 2011).”

Another multicenter prospective trial of 4203 patients studied the use of WATS^{3D} as an adjunct to four-quadrant random forceps biopsy (FB) in detecting Barrett’s esophagus (BE) and esophageal dysplasia (ED). FB alone detected 594 cases of BE, and the addition of WATS^{3D} detected an additional 493 cases, an increase of 83%. Likewise, WATS^{3D} detected an increase of 88.5% of low-grade dysplasia (LGD). The authors conclude, “Adjunctive use of WATS to FB significantly improves the detection of both BE and ED. Sampling effort, an inherent limitation associated with screening and surveillance, can be improved with WATS allowing better informed decisions to be made about the management and subsequent treatment of these patients (Gross et al., 2018).” These findings support the earlier study by Johanson and colleagues. In their study of 1266 patients being screened for BE and ED, they noted an overall increase of 39.8% in the detection of BE when WATS^{3D} (brush biopsy or BB) was used as an adjunct to FB. They also

Esophageal Pathology Testing AHS – M2171

report that the number of patients needed to test (NNT) to obtain a positive BE result was 8.7. Interestingly, specifically for patients with gastroesophageal reflux disease (GERD), the addition of WATS^{3D} resulted in an even higher increase in the detection of BE (by 70.5%) (Johanson, Frakes, & Eisen, 2011).

Another study published in 2018 of a randomized trial at 16 different medical centers (n = 160 patients) compared the order of testing (WATS^{3D} followed by biopsy sampling versus biopsy sampling followed by WATS^{3D}) to detect high-grade dysplasia/esophageal adenocarcinoma (HGD/EAC). The authors also stated secondary aims of determining the amount of additional time required for WATS^{3D} and the ability of each procedure to separately detect neoplasia. The order of the procedures was not statistically relevant. The use of WATS^{3D} as an adjunct to biopsy did result in a 14.4% absolute increase in the number of HGD/EAC cases detected. The authors noted that WATS^{3D}, on average, adds 4.5 minutes to the total procedure time. They conclude, “Results of this multicenter, prospective, randomized trial demonstrate that the use of WATS in a referral BE population increases the detection of HGD/EAC (Vennalaganti et al., 2018).”

Evidence summary WATS-3D

Overall, the quality of evidence related to use of WATS-3D in Barrett’s esophagus (BE) for screening or surveillance is low. The published literature consists of five, industry-funded studies of diagnostic yield, all at high risk of bias, with unclear benefit in net health outcomes. In addition, the performance characteristics of WATS-3D, including false positive and negative rates are unknown, and risks associated with overdiagnosis and overtreatment require elucidation.

In the published surveillance studies using adjunctive WATS-3D, relative diagnostic yields for BE and various categories of dysplasia have ranged from 18.8% to 73% and 42.1% to 428.6%, respectively. These studies are limited by heterogeneity in classification and reporting of test results and selection bias stemming from enrichment with patients with a prior history of high-grade dysplasia and adenocarcinoma. It is also unclear to what extent results obtained from academic centers are generalizable to community-based settings, where adherence to endoscopic biopsy guidelines is poor, and where, in a nonenriched community setting most patients with BE undergoing surveillance have no dysplasia. In discordant cases where BE or dysplasia were identified only by WATS-3D, significant physician management changes included initiation of invasive treatments, however, health outcomes stemming from management changes were not reported, and follow-up data on disease progression in these patients are limited. No direct evidence of clinical utility was identified.

In the published studies using WATS-3D in individuals at increased risk of BE who underwent standard screening with adjunctive WATS-3D, relative diagnostic yields for BE and dysplasia have ranged from 75% to 213% and 88.5% to 274%, respectively. However, available studies have incomplete descriptions of selection criteria, and it is unclear whether study patients are at increased risk as defined by guideline recommendations for screening. In fact, 2 studies were enriched with women in whom screening is generally not recommended by society guidelines. These studies also noted that detected cases of BE in short-segment patients may have reflected intestinal metaplasia of the cardia, which is thought to carry a significantly lower risk of cancer development compared to traditional BE. In discordant cases where BE or dysplasia were identified only by WATS-3D, significant physician management changes included initiation of invasive treatments, however, health outcomes from management changes were not reported, and follow-up data on disease progression in these patients are limited. No direct evidence of clinical utility was identified.

Because combined use of WATS-3D with standard screening or surveillance is intended to replace the current standard of care for guiding patient management decisions regarding initiation of treatment or surveillance, direct evidence of clinical utility is required (that is, comparing health outcomes for

Esophageal Pathology Testing AHS – M2171

patients managed with and without the test). The current published evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Guidelines and Recommendations

United European Gastroenterology (UEG), The European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), the European Academy of Allergy and Clinical Immunology (EAACI), and the European Society of Eosinophilic Oesophagitis (EUREOS) (Lucendo et al., 2017)

These joint guidelines were published by a task force of 21 physicians and researchers for eosinophilic esophagitis (EoE). In it, they note that noninvasive biomarkers (inflammatory factors, total IgE, chemokines, tryptase, et al) are “not accurate” to diagnose or monitor EoE. They remark that absolute serum eosinophil count fared best in correlating with severity of disease but had a diagnostic accuracy of 0.754. The guidelines state that histology is necessary for monitoring. The String Test was also mentioned as having good preliminary results but required further corroboration (Lucendo et al., 2017).

Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference (Dellon et al., 2018)

These newly published international diagnostic criteria primarily include endoscopic findings. Although the guidelines emphasize ruling out other diagnoses (in which biomarkers may be useful), it does not mention any serum or genetic factors for EoE itself (Dellon et al., 2018).

National Comprehensive Cancer Network (NCCN, 2020c)

The NCCN notes four syndromes that predispose to an increased risk for esophageal and esophagogastric junction (EGJ) cancers; tylosis with non-epidermolytic palmoplantar keratoderma (PPK) with esophageal cancer (including Howel-Evans syndrome), familial Barrett esophagus (FBE), Bloom Syndrome (BS, *BLM* gene), and Fanconi Anemia (FA, *FANCA-E genes*). The *RHBDF2* gene has been associated with tylosis (with non-epidermolytic palmoplantar keratosis) for genetic risk assessment. Though FBE may be associated with “one or more autosomally inherited dominant susceptibility alleles,” no gene has been validated. With regards to next-generation sequencing, the NCCN concludes that “when limited tissue is available for testing, sequential testing of single biomarkers or use of limited molecular diagnostic panels may quickly exhaust the sample. In these scenarios, comprehensive genomic profiling via a validated NGS assay performed in a CLIA-approved laboratory may be used for the identification of *HER2* amplification, MSI [microsatellite instability], and *NTRK* gene fusions. It should be noted that NGS has several inherent limitations and thus whenever possible, the use of gold-standard assays (IHC [immunohistochemistry]/FISH [fluorescence *in situ* hybridization]/targeted PCR [polymerase chain reaction]) should be performed” (NCCN, 2020b).

Liquid biopsy aids in identifying genetic mutations in solid cancers by looking at circulating tumor DNA (ctDNA) in blood and can be used in those with advanced disease and cannot undergo clinical biopsies for disease surveillance and management. Detecting mutations in DNA from esophageal and EGJ carcinomas “can identify targetable alterations or the evolution of clones with altered treatment response profiles.” The NCCN has also stated that “a negative

Esophageal Pathology Testing AHS – M2171

result should be interpreted with caution, as this does not exclude the presence of tumor mutations or amplifications” (NCCN, 2020b).

The NCCN notes that “testing for MSI by polymerase chain reaction (PCR) or *MMR* [mismatch repair] by IHC should be considered on locally advanced, recurrent, or metastatic esophageal and EGJ cancers in patients who are candidates for treatment with PD-1 inhibitors.” The NCCN also identifies three targeted therapeutic agents currently approved by the FDA; trastuzumab, ramucirumab, and pembrolizumab. Trastuzumab is based on HER2 status and pembrolizumab is based on “testing for MSI by PCR/MMR by IHC or PD-LA expression by CPS [combined positive score].” Select TRK inhibitors have also been FDA-approved for *NTRK* gene fusion-positive tumors (NCCN, 2020b).

Genetic biomarkers such as aneuploidy and loss of p53 heterozygosity have been proposed as useful for identifying increased risk of progression in BE patients, but the NCCN remarks that these biomarkers require “further prospective evaluation as predictors of risk for the development of HGD [high-grade dysplasia] and adenocarcinoma of the esophagus in patients with Barrett esophagus” (NCCN, 2020b).

The NCCN notes that wide-area transepithelial sampling (WATS) has been used to detect esophageal carcinomas in BE patients. They state, “The use of wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS3D), a relatively new sampling technique combining an abrasive brush biopsy of the Barrett esophagus mucosa with computer-assisted pathology analysis to highlight abnormal cells, may help increase the detection of esophageal dysplasia in patients with Barrett esophagus.” They go on to cite the 2017 study by Vennalaganti and colleagues that shows a 14.4% increase in the number of additional cases of HGD/esophageal adenocarcinoma captured by using WATS. However, the NCCN remarks that the “utility and accuracy of WATS for detecting HGD/adenocarcinoma in patients with Barrett esophagus needs to be evaluated in larger phase III randomized trials” (NCCN, 2020b).

American Society for Gastrointestinal Endoscopy (Qumseya et al., 2019)

The ASGE recommends the use of WATS3D as an adjunct to “Seattle protocol biopsy sampling” in patients with known or suspected BE (conditional recommendation, low quality of evidence). The society stated that they had downrated the certainty of the recommendation due to possible risk bias, inconsistency, and indirectness of the studies that were available at the time of publication since some of the studies had included LGD (whereas others had not) and many of the studies had been sponsored by the test’s manufacturer. The society also had noted that, as of the date of publication, no studies addressing the cost-effectiveness of WATS-3D had been published. (Qumseya et al., 2019a) It should be noted that since the publication of these guidelines the 2020 cost-effectiveness study by Singer and Smith (2020) has been published.

Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Technology and Value Assessment Committee (TVAC) (Docimo, Al-Mansour, & Tsuda, 2020)

The TVAC of SAGES evaluated WATS^{3D} and published their findings and recommendations within the journal *Surgical Endoscopy* in 2020. They note that WATS^{3D} is not recommended “as a stand-alone substitute for cold forcep biopsies.” Within their expert panel recommendation section:

Esophageal Pathology Testing AHS – M2171

- They state that no significant morbidity or mortality is associated with the testing.
- They also state that “WATS^{3D} increases diagnostic yield by 38 – 150% for Barrett’s Esophagus, by 40 – 150% for Low Grade Dysplasia; and by 420% for High Grade Dysplasia; when compared to forceps biopsy alone.”
- WATS^{3D} testing also “has very high inter-observer agreement for the pathological diagnosis of non-dysplastic and dysplastic Barrett’s Esophagus.”

Regarding value, “Increased detection of pre-malignant diseases of the esophagus by the adjunctive use of WATS^{3D} supports screening and surveillance by the adjunctive use of WATS^{3D} during upper endoscopy in appropriate patients” (Docimo et al., 2020).

American Foregut Society (AFS, 2020)

The AFS published a white paper reviewing WATS^{3D} in 2020. After reviewing the literature, they state, “The American Foregut Society (AFS) Board has concluded that there are sufficient data to support the routine use of WATS^{3D} technology in the diagnosis and ongoing evaluation of Barrett’s esophagus” (AFS, 2020).

American College of Gastroenterology (ACG, 2016)

The ACG published guidelines on the diagnosis and management of Barrett Esophagus. In it, they state that no single biomarker (including genetic abnormalities) is “adequate” as a risk stratification tool. Further, they remark that an entire panel of biomarkers may be required, but no panels were ready for clinical practice (Shaheen, Falk, Iyer, & Gerson, 2016).

European Society for Medical Oncology (ESMO, 2016)

ESMO does not mention any molecular testing for diagnosis or risk assessment of esophageal cancer. Testing for HER2 is mentioned for targeted therapy with trastuzumab. The guidelines recommend following the 2016 ACG guidelines regarding Barrett’s Esophagus screening (Lordick et al., 2016)

Pan-Asian adapted ESMO Clinical Practice Guidelines: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (Muro et al., 2019)

The only biomarker mentioned in these guidelines is HER2; intended “to select patients with metastatic oesophageal adenocarcinoma for treatment with...trastuzumab”. The guidelines go on to state that evidence for the role of other biomarkers or agents is “limited” (Muro et al., 2019).

Applicable Federal Regulations

A search for “esophagus” on the FDA website on 1/20/2021 yielded 0 relevant results. A search of the FDA device database on 1/20/2021 using the query “WATS” or “transepithelial” yielded no relevant results. Likewise, a search of the CMS database of the active LCD/NCDs for “WATS3D” yielded no results. Additionally, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88). As an LDT, the U. S. Food and

Esophageal Pathology Testing AHS – M2171

Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 81301, 81479, 88104, 88271, 88272, 88273, 88274, 88275, 88341, 88342, 88344, 88360, 88361, 88367, 88368, 88369, 88373, 88374, 88377, 0095U, 0108U, 0114U

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

- Ackerman, S. J., Kagalwalla, A. F., Hirano, I., Gonsalves, N., Katcher, P. M., Gupta, S., . . . Furuta, G. T. (2019). One-Hour Esophageal String Test: A Nonendoscopic Minimally Invasive Test That Accurately Detects Disease Activity in Eosinophilic Esophagitis. *Am J Gastroenterol*, *114*(10), 1614-1625. doi:10.14309/ajg.0000000000000371
- AFS. (2020). Wide Area Transepithelial Sampling with Computer Assisted 3D Analysis (WATS3D). Retrieved from <https://www.americanforegutsociety.org/wp-content/uploads/2020/01/CDX-white-paper.pdf>
- Anandasabapathy, S., Sontag, S., Graham, D. Y., Frist, S., Bratton, J., Harpaz, N., & Waye, J. D. (2011). Computer-assisted brush-biopsy analysis for the detection of dysplasia in a high-risk Barrett's esophagus surveillance population. *Dig Dis Sci*, *56*(3), 761-766. doi:10.1007/s10620-010-1459-z
- Bonis, P. A. L., & Gupta, S. K. (2020, February 17). Clinical manifestations and diagnosis of eosinophilic esophagitis. Retrieved from <https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-eosinophilic-esophagitis>
- Cernostics. (2021). What is the TissueCypher® Barrett's Esophagus Assay? Retrieved from <http://www.cernostics.com/products/>
- Costa-Barbosa, F. A., Balasubramanian, R., Keefe, K. W., Shaw, N. D., Al-Tassan, N., Plummer, L., . . . Crowley, W. F., Jr. (2013). Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. *J Clin Endocrinol Metab*, *98*(5), E943-953. doi:10.1210/jc.2012-4116
- Critchley-Thorne, R. J., Duits, L. C., Prichard, J. W., Davison, J. M., Jobe, B. A., Campbell, B. B., . . . Falk, G. W. (2016). A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. *Cancer Epidemiol Biomarkers Prev*, *25*(6), 958-968. doi:10.1158/1055-9965.Epi-15-1164
- Dellon, E. S., Liacouras, C. A., Molina-Infante, J., Furuta, G. T., Spergel, J. M., Zevit, N., . . . Bredenoord, A. J. (2018). Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. *Gastroenterology*, *155*(4), 1022-1033.e1010. doi:10.1053/j.gastro.2018.07.009
- Diagnostics, C. (2021). WATS3D empowers physicians to preempt cancer. Retrieved from <https://www.cdxdiagnostics.com/wats3d>
- Docimo, S., Jr., Al-Mansour, M., & Tsuda, S. (2020). SAGES TAVAC safety and efficacy analysis WATS(3D) (CDx Diagnostics, Suffern, NY). *Surg Endosc*. doi:10.1007/s00464-020-07503-w

Esophageal Pathology Testing AHS – M2171

- Eluri, S., Klaver, E., Duits, L. C., Jackson, S. A., Bergman, J. J., & Shaheen, N. J. (2018). Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma. *Dis Esophagus*, *31*(11). doi:10.1093/dote/doy026
- EnteroTrack. (2019). The EnteroTracker®. Retrieved from <https://enterotracker.com/enterotracker-overview>
- Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S., . . . Fitzgerald, R. C. (2019). The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. *Nat Genet*, *51*(3), 506-516. doi:10.1038/s41588-018-0331-5
- Gibson, M. (2020, April 14). Epidemiology and pathobiology of esophageal cancer. Retrieved from <https://www.uptodate.com/contents/epidemiology-and-pathobiology-of-esophageal-cancer>
- Gonzaga, I. M., Soares Lima, S. C., Nicolau, M. C., Nicolau-Neto, P., da Costa, N. M., de Almeida Simao, T., . . . Ribeiro Pinto, L. F. (2017). TFF1 hypermethylation and decreased expression in esophageal squamous cell carcinoma and histologically normal tumor surrounding esophageal cells. *Clin Epigenetics*, *9*, 130. doi:10.1186/s13148-017-0429-0
- Gross, S. A., Smith, M. S., & Kaul, V. (2018). Increased detection of Barrett's esophagus and esophageal dysplasia with adjunctive use of wide-area transepithelial sample with three-dimensional computer-assisted analysis (WATS). *United European Gastroenterol J*, *6*(4), 529-535. doi:10.1177/2050640617746298
- Hao, J., Critchley-Thorne, R., Diehl, D. L., & Snyder, S. R. (2019). A Cost-Effectiveness Analysis Of An Adenocarcinoma Risk Prediction Multi-Biomarker Assay For Patients With Barrett's Esophagus. *Clinicoecon Outcomes Res*, *11*, 623-635. doi:10.2147/ceor.S221741
- Interpace. (2019). An Innovative Diagnostic Tool for Barrett's Esophagus Patients. Retrieved from <https://barregen.com/>
- Johanson, J. F., Frakes, J., & Eisen, D. (2011). Computer-assisted analysis of abrasive transepithelial brush biopsies increases the effectiveness of esophageal screening: a multicenter prospective clinical trial by the EndoCDx Collaborative Group. *Dig Dis Sci*, *56*(3), 767-772. doi:10.1007/s10620-010-1497-6
- Li, J., Qi, Z., Hu, Y. P., & Wang, Y. X. (2019). Possible biomarkers for predicting lymph node metastasis of esophageal squamous cell carcinoma: a review. *J Int Med Res*, *47*(2), 544-556. doi:10.1177/0300060518819606
- Lordick, F., Mariette, C., Haustermans, K., Obermannová, R., Arnold, D., & on behalf of the, E. G. C. (2016). Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Annals of Oncology*, *27*(suppl_5), v50-v57. doi:10.1093/annonc/mdw329
- Lucendo, A. J., Molina-Infante, J., Arias, A., von Arnim, U., Bredenoord, A. J., Bussmann, C., . . . Attwood, S. E. (2017). Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. *United European Gastroenterol J*, *5*(3), 335-358. doi:10.1177/2050640616689525
- McLaren, P. J., Barnes, A. P., Terrell, W. Z., Vaccaro, G. M., Wiedrick, J., Hunter, J. G., & Dolan, J. P. (2017). Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma. *Am J Surg*, *213*(5), 915-920. doi:10.1016/j.amjsurg.2017.03.024
- Moinova, H. R., LaFramboise, T., Lutterbaugh, J. D., Chandar, A. K., Dumot, J., Faulx, A., . . . Markowitz, S. D. (2018). Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. *Sci Transl Med*, *10*(424). doi:10.1126/scitranslmed.aao5848
- Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., . . . Douillard, J. Y. (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Ann Oncol*, *30*(1), 34-43. doi:10.1093/annonc/mdy498
- NCCN. (2019). Esophageal and Esophagogastric Junction Cancers. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
- NCCN. (2020a, August 14). Esophageal and Esophagogastric Junction Cancers. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
- NCCN. (2020b). Esophageal and Esophagogastric Junction Cancers - Version 5.2020 - December 23, 2020. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

Esophageal Pathology Testing AHS – M2171

- NCCN. (2020c, December 23). NCCN Guidelines Version 5.2020: Esophageal and Esophagogastric Junction Cancers. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
- Plum, P. S., Gebauer, F., Krämer, M., Alakus, H., Berlth, F., Chon, S. H., . . . Loeser, H. (2019). HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. *BMC Cancer*, *19*(1), 38. doi:10.1186/s12885-018-5242-4
- Qumseya, B., Sultan, S., Bain, P., Jamil, L., Jacobson, B., Anandasabapathy, S., . . . Wani, S. (2019a). ASGE guideline on screening and surveillance of Barrett's esophagus. *Gastrointestinal Endoscopy*, *90*(3), 335-359.e332. doi:10.1016/j.gie.2019.05.012
- Qumseya, B., Sultan, S., Bain, P., Jamil, L., Jacobson, B., Anandasabapathy, S., . . . Wani, S. (2019b). ASGE guideline on screening and surveillance of Barrett's esophagus. *Gastrointestinal Endoscopy*, *90*(3), 335-359.e332. doi:10.1016/j.gie.2019.05.012
- Rothenberg, M. E. (2020). Eosinophilic esophagitis (EoE): Genetics and immunopathogenesis. Retrieved from <https://www.uptodate.com/contents/eosinophilic-esophagitis-eoe-genetics-and-immunopathogenesis>
- Saltzman, J. R., & Gibson, M. K. (2018, October 22). Clinical manifestations, diagnosis, and staging of esophageal cancer. Retrieved from <https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-esophageal-cancer>
- Saltzman, J. R., & Gibson, M. K. (2020). Clinical manifestations, diagnosis, and staging of esophageal cancer. Retrieved from <https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-staging-of-esophageal-cancer>
- Shaheen, N. J., Falk, G. W., Iyer, P. G., & Gerson, L. B. (2016). ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *III*(1), 30-50. doi:10.1038/ajg.2015.322
- Sherrill, J. D., & Rothenberg, M. E. (2014). Genetic and epigenetic underpinnings of eosinophilic esophagitis. *Gastroenterol Clin North Am*, *43*(2), 269-280. doi:10.1016/j.gtc.2014.02.003
- Shoda, T., Wen, T., Aceves, S. S., Abonia, J. P., Atkins, D., Bonis, P. A., . . . Rothenberg, M. E. (2018). Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. *Lancet Gastroenterol Hepatol*, *3*(7), 477-488. doi:10.1016/s2468-1253(18)30096-7
- Singer, M. E., & Smith, M. S. (2020). Wide Area Transepithelial Sampling with Computer-Assisted Analysis (WATS(3D)) Is Cost-Effective in Barrett's Esophagus Screening. *Dig Dis Sci*. doi:10.1007/s10620-020-06412-1
- Smith, M. S., Ikonomi, E., Bhuta, R., Iorio, N., Kataria, R. D., Kaul, V., & Gross, S. A. (2019). Wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS) markedly improves detection of esophageal dysplasia and Barrett's esophagus: analysis from a prospective multicenter community-based study. *Dis Esophagus*, *32*(3). doi:10.1093/dote/doy099
- Spechler, S. (2020, September 8). Barrett's esophagus: Epidemiology, clinical manifestations, and diagnosis. Retrieved from <https://www.uptodate.com/contents/barretts-esophagus-epidemiology-clinical-manifestations-and-diagnosis>
- Testa, U., Castelli, G., & Pelosi, E. (2017). Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. *Medicines (Basel)*, *4*(3). doi:10.3390/medicines4030067
- Trindade, A. J., McKinley, M. J., Alshelleh, M., Levi, G., Stewart, M., Quinn, K. J., & Thomas, R. M. (2019). Mutational load may predict risk of progression in patients with Barrett's oesophagus and indefinite for dysplasia: a pilot study. *BMJ Open Gastroenterology*, *6*(1), e000268. doi:10.1136/bmjgast-2018-000268
- Vennalaganti, P. R., Kaul, V., Wang, K. K., Falk, G. W., Shaheen, N. J., Infantolino, A., . . . Sharma, P. (2018). Increased detection of Barrett's esophagus-associated neoplasia using wide-area trans-epithelial sampling: a multicenter, prospective, randomized trial. *Gastrointest Endosc*, *87*(2), 348-355. doi:10.1016/j.gie.2017.07.039
- Visser, E., Franken, I. A., Brosens, L. A., Ruurda, J. P., & van Hillegersberg, R. (2017). Prognostic gene expression profiling in esophageal cancer: a systematic review. *Oncotarget*, *8*(3), 5566-5577. doi:10.18632/oncotarget.13328
- Vollmer, R. T. (2019). A review of the incidence of adenocarcinoma detected during surveillance for Barrett's esophagus. *Hum Pathol*, *84*, 150-154. doi:10.1016/j.humphath.2018.09.016

Esophageal Pathology Testing AHS – M2171

Wen, T., Stucke, E. M., Grotjan, T. M., Kemme, K. A., Abonia, J. P., Putnam, P. E., . . . Rothenberg, M. E. (2013). Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. *Gastroenterology*, *145*(6), 1289-1299. doi:10.1053/j.gastro.2013.08.046

Zhang, X., Patil, D., Odze, R. D., Zhao, L., Lisovsky, M., Guindi, M., . . . Appelman, H. D. (2018). The microscopic anatomy of the esophagus including the individual layers, specialized tissues, and unique components and their responses to injury. *Ann N Y Acad Sci*, *1434*(1), 304-318. doi:10.1111/nyas.13705

Specialty Matched Consultant Advisory Panel review 11/2020.

Medical Director review 11/2020

BCBSA Medical Policy Reference Manual [Electronic Version]. 7.01.167, 8/2021

Medical Director review 8/2021

Specialty Matched Consultant Advisory Panel review 11/2021

Medical Director review 11/2021

Policy Implementation/Update Information

- 5/12/20 New policy developed. BCBSNC will provide coverage for esophageal pathology testing when it is determined to be medically necessary because the medical criteria and guidelines are met. Medical Director review 4/2020. **Policy noticed 5/12/2020 for effective date 7/21/2020.** (jd)
- 12/8/20 Specialty Matched Consultant Advisory Panel review 11/2020. Medical Director review 11/2020. (jd)
- 2/9/21 Annual review by Avalon 4th Qtr 2020 CAB. Minor revision to the description section and added the following under Related Policies: “Detection of Circulating Tumor Cells and Cell Free DNA in Cancer Management (Liquid Biopsy) AHS – G2054”. Item #4 under When Not Covered section changed from investigation to “Reimbursement is not allowed...”. Policy guidelines and references updated. Medical Director review 1/2020. (jd)
- 5/4/21 Reviewed by Avalon 1st Quarter 2021 CAB. Policy guidelines and references updated. Medical Director review 4/2021. (jd)
- 9/7/21 Minor wording revision for clarity to When Not Covered section item #5 (WATS-3D), policy guidelines updated with evidence summary for WATS-3D, and references updated. Medical Director review 8/2021. (jd)
- 11/30/21 Specialty Matched Consultant Advisory Panel review 11/2021. Medical Director review 11/2021. (jd)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.